Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14681741 | 0.80 | TPI1 (0.43) | AAK1APLNRKDM4E | |
| SCHEMBL19821855 | 0.79 | MCL1 (0.37) | LMNAMCL1POLBALDH1A1L3MBTL1 | |
| SCHEMBL9962283 | 0.78 | TSHR (0.44) | LMNAPOLBALDH1A1MAPTMAPK1 | |
| SCHEMBL4090082 | 0.78 | CTSD (0.41) | LMNAAAK1ALDH1A1MAPTAPLNR | |
| SCHEMBL13765205 | 0.76 | LMNA (0.43) | LMNAMCL1POLBALDH1A1MAPT | |
| SCHEMBL13225634 | 0.76 | TSHR (0.36) | AAK1APLNRMAPK1 | |
| SCHEMBL19010423 | 0.76 | MCL1 (0.40) | LMNAMCL1AAK1ALDH1A1L3MBTL1 | |
| SCHEMBL15177251 | 0.76 | POLB (0.31) | LMNAMCL1POLBALDH1A1KDM4E | |
| SCHEMBL12859140 | 0.75 | LMNA (0.41) | LMNAPOLBALDH1A1L3MBTL1MAPT | |
| SCHEMBL25942492 | 0.75 | MEN1 (0.43) | POLBALDH1A1MAPK1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129982-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20210040111-A1 | DRUGS TO TREAT OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| US-20100125069-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-7425552-B2 | Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction | ANADYS PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070299095-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299095-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | LMNA 2397/4885MCL1 158/4885AAK1 1201/4885 |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | LMNA 1762/4885MCL1 471/4885AAK1 910/4885 |
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | SNCA, MAPT, HTT | LMNA 1589/4885MCL1 2743/4885AAK1 171/4885 |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | AHR, HCAR2, HCAR1 | LMNA 2992/4885MCL1 3292/4885AAK1 3049/4885 |
| US-20210040111-A1 | DRUGS TO TREAT OCULAR DISORDERS | PDE6C, AGER, PDE6A | LMNA 1763/4885MCL1 3724/4885AAK1 2880/4885 |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | LMNA 1648/4885MCL1 295/4885AAK1 2541/4885 |
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | LMNA 3964/4885MCL1 1578/4885AAK1 678/4885 |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | LMNA 2397/4885MCL1 158/4885AAK1 1201/4885 |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | LMNA 2397/4885MCL1 158/4885AAK1 1201/4885 |
| US-20100125069-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | SSB, TYMS, TPMT | LMNA 1834/4885MCL1 3134/4885AAK1 1299/4885 |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | LMNA 3964/4885MCL1 1578/4885AAK1 678/4885 |
| US-20070299095-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | LMNA 1834/4885MCL1 3134/4885AAK1 1299/4885 |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | EZH2, BMI1, EZH1 | LMNA 3180/4885MCL1 644/4885AAK1 1954/4885 |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | AR, NR5A1, LHCGR | LMNA 3964/4885MCL1 1578/4885AAK1 678/4885 |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | LMNA 4065/4885MCL1 646/4885AAK1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.